These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38252942)

  • 1. Gene Therapy Versus Common Care for Eligible Individuals With Sickle Cell Disease in the United States : A Cost-Effectiveness Analysis.
    Basu A; Winn AN; Johnson KM; Jiao B; Devine B; Hankins JS; Arnold SD; Bender MA; Ramsey SD
    Ann Intern Med; 2024 Feb; 177(2):155-164. PubMed ID: 38252942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distributional Cost-Effectiveness of Equity-Enhancing Gene Therapy in Sickle Cell Disease in the United States.
    Goshua G; Calhoun C; Ito S; James LP; Luviano A; Krishnamurti L; Pandya A
    Ann Intern Med; 2023 Jun; 176(6):779-787. PubMed ID: 37247420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States.
    Herring WL; Gallagher ME; Shah N; Morse KC; Mladsi D; Dong OM; Chawla A; Leiding JW; Zhang L; Paramore C; Andemariam B
    Pharmacoeconomics; 2024 Jun; 42(6):693-714. PubMed ID: 38684631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of a hypothetical cell or gene therapy cure for sickle cell disease.
    Salcedo J; Bulovic J; Young CM
    Sci Rep; 2021 May; 11(1):10838. PubMed ID: 34035408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis.
    Neilan AM; Landovitz RJ; Le MH; Grinsztejn B; Freedberg KA; McCauley M; Wattananimitgul N; Cohen MS; Ciaranello AL; Clement ME; Reddy KP; Hyle EP; Paltiel AD; Walensky RP
    Ann Intern Med; 2022 Apr; 175(4):479-489. PubMed ID: 35099992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Choe JH; Abdel-Azim H; Padula WV; Abou-El-Enein M
    JAMA Netw Open; 2022 Dec; 5(12):e2245956. PubMed ID: 36520440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness Analysis of Lung Cancer Screening in the United States: A Comparative Modeling Study.
    Criss SD; Cao P; Bastani M; Ten Haaf K; Chen Y; Sheehan DF; Blom EF; Toumazis I; Jeon J; de Koning HJ; Plevritis SK; Meza R; Kong CY
    Ann Intern Med; 2019 Dec; 171(11):796-804. PubMed ID: 31683314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population-Wide Screening for Chronic Kidney Disease : A Cost-Effectiveness Analysis.
    Cusick MM; Tisdale RL; Chertow GM; Owens DK; Goldhaber-Fiebert JD
    Ann Intern Med; 2023 Jun; 176(6):788-797. PubMed ID: 37216661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
    Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
    Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis.
    Walensky RP; Horn T; McCann NC; Freedberg KA; Paltiel AD
    Ann Intern Med; 2020 May; 172(9):583-590. PubMed ID: 32150602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the Value of Sarilumab Monotherapy for Adults with Moderately to Severely Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis.
    Whittington MD; McQueen RB; Ollendorf DA; Chapman RH; Kumar VM; Synnott PG; Agboola F; Campbell JD
    J Manag Care Spec Pharm; 2019 Jan; 25(1):80-87. PubMed ID: 30589626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness Modeling of Prostate-Specific Membrane Antigen Positron Emission Tomography with Piflufolastat F 18 for the Initial Diagnosis of Patients with Prostate Cancer in the United States.
    Yee CW; Harvey MJ; Xin Y; Kirson NY
    Pharmacoeconomics; 2024 Feb; 42(2):231-247. PubMed ID: 37934376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple Therapy Versus Biologic Therapy for Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis.
    Bansback N; Phibbs CS; Sun H; O'Dell JR; Brophy M; Keystone EC; Leatherman S; Mikuls TR; Anis AH;
    Ann Intern Med; 2017 Jul; 167(1):8-16. PubMed ID: 28554192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular assist devices as either bridge to transplant or alternative to transplant for adults eligible for heart transplantation: systematic review and cost-effectiveness model.
    Sutcliffe P; Connock M; Pulikottil-Jacob R; Kandala NB; Suri G; Gurung T; Grove A; Shyangdan D; Briscoe S; Maheswaran H; Clarke A
    Health Technol Assess; 2013 Nov; 17(53):1-499, v-vi. PubMed ID: 24280231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Budget Impact Analysis of Gene Therapy for Sickle Cell Disease: The Medicaid Perspective.
    DeMartino P; Haag MB; Hersh AR; Caughey AB; Roth JA
    JAMA Pediatr; 2021 Jun; 175(6):617-623. PubMed ID: 33749717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation.
    Cherry MG; Greenhalgh J; Osipenko L; Venkatachalam M; Boland A; Dundar Y; Marsh K; Dickson R; Rees DC
    Health Technol Assess; 2012; 16(43):1-129. PubMed ID: 23140544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of financial incentives for improving diet and health through Medicare and Medicaid: A microsimulation study.
    Lee Y; Mozaffarian D; Sy S; Huang Y; Liu J; Wilde PE; Abrahams-Gessel S; Jardim TSV; Gaziano TA; Micha R
    PLoS Med; 2019 Mar; 16(3):e1002761. PubMed ID: 30889188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.